Načítá se...
Novel targeted therapeutics for metastatic castration-resistant prostate cancer
Virtually all patients that succumb to prostate cancer die of metastatic castration-resistant disease. Although docetaxel is the standard of care for these patients and is associated with a modest prolongation of survival, there is an urgent need for novel treatment strategies for metastatic prostat...
Uloženo v:
| Hlavní autoři: | , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2009
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4029098/ https://ncbi.nlm.nih.gov/pubmed/19717225 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.canlet.2009.08.012 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|